Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Cyclic tetramer compounds as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders

Cyclic tetramer compounds as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders

US Patent 11813306 · Granted Nov 14, 2023

Estimated economic value: $118,408,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Enhanced MAC-CE and RRC IE for multi-carrier configurations2025
Two-step random access channel signaling2025
Updating PUCCH spatial relation information2025
Multiple component carrier simultaneous transmission control indicator state act2025
Parallel handover and failure handling2025
Constellation shaping-related coding selection2025
Random access channel occasion configuration2025
Techniques for managing sessions in multiple-subscription wireless communication2025
Cyclic peptides as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibit2025
Cyclic peptides as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibit2025
Cyclic peptides as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibit2025
Cyclic peptides as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibit2025